15.05.2017 • News

ExxonMobil Confirms Jurong Aromatics Acquisition

(c) JAC
(c) JAC

Following local media reports in March, ExxonMobil has confirmed it has agreed to buy the Singapore aromatics plant of Jurong Aromatics Corp. (JAC). Financial terms of the transaction, which is expected to close in the second half of 2017, were not disclosed.

The US oil, gas and chemicals group said the facility, said to be one of the world’s largest aromatics plants with a capacity of 1.4 million t/y, will enable the cost-competitive growth of its aromatics business. ExxonMobil added that proximity to its integrated refining and chemical complex in Singapore will strengthen both sites with product and logistical synergies.

“Our growth in Singapore is driven by the expected increase in global demand for chemical products over the next decade of nearly 45 percent, or about 4 percent per year, which is a faster pace than energy demand and economic growth,” said, Neil Chapman, president of ExxonMobil Chemical. “Nearly three-quarters of the increased demand is expected to be in Asia-Pacific as a result of its rising prosperity and a growing middle class.”

The country is home to ExxonMobil’s largest integrated refining and petrochemical complex, which processes 592,000 barrels of crude oil per day and includes two steam crackers. The addition of JAC’s aromatics plant will raise the US group’s aromatics production in Singapore to above 3.5 million t/y, of which 1.8 million t/y is paraxylene.

Later this year, a 230,000 t/y specialty polymers plant producing halobutyl rubber and performance resins for adhesive applications will start up in phases at the complex.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.